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Background: Penicillin is recommended as the ﬁrst-line agent
for intrapartum antibiotic prophylaxis, while ampicillin is con-
sidered as an acceptable alternative. Although GBS strains are
generally susceptible to penicillin with only occasional resistance,
they show varying resistance to erythromycin, clindamycin and
tetracycline. Therefore, a knowledge of the resistance proﬁle of GBS
in the local environmentwill be useful for administration of appro-
priateintrapartumantibiotics prophylaxis.
Methods & Materials: Rectovaginal swabs collected from
pregnant women were cultured for GBS using conventional
media.Kirby-Bauer disc diffusion method was performed accord-
ing to the Clinical Laboratory Standards Institute (CLSI) guidelines
on GBS isolates to determine the antibiotic susceptibility pat-
terns of the isolates. Inducible clindamycin resistancewas detected
by using the D-zone test. Resistance determinants were dis-
cerned with conventional PCR. Streptococcus agalactiae control
strainsIa (2008232728),Ib (2008232729),III (2008232582) andV
(2008232731) from CDC were usedfor quality control of antibiotic
susceptibility testing.
Results: All 46 available strains of GBS colonizing the pregnant
mothers were uniformly susceptible (100%) to penicillin, van-
comycin and ceftriaxone, while 44 (95.7%) and 41 (89.1%) were
resistant to tetracycline and trimethoprim- sulfamethoxazole
respectively (Table 2). Only three (6.5%) of the isolates showed
erythromycin-clindamycin inducible resistance. ermA gene was
present in all three GBS isolates with erythromycin-clindamycin
inducible resistance and absent in the only one strain with inter-
mediate resistance. ermB was absent in all the four strains tested
while the mefA/E gene was carried by two of the macrolide- clin-
damycin resistance isolates. tetM gene was carried by all isolates
that showed tetracycline resistance phenotypes.
Antibiotic Susceptibility Proﬁle of maternal GBS Strains
Antibiotic Susceptibility, % Intermediate
susceptibility, %
Resistance, %
Penicillin G (10U) 46 (100) - -
Erythromycin (15ug) 43 (93.5) - 3 (6.5)
Clindamycin (2ug) 42 (91.2) 1 (2.3) 3 (6.5)
Vancomycin (30ug) 46 (100) - -
Tetracycline (30ug) 2 (4.3) - 44 (95.7)
Ceftraixone (30ug) 46 (100) - -
Ciproﬂoxaxin (5ug) 46 (100) - -
SXT (1.25/23.75ug) 5 (10.9) - 41 (89.1)
SXT: Trimethoprim- Sulfamethoxazole
(n =46)
Conclusion: In this study, all GBS isolates were susceptible to
PenicillinG, the recommended antibiotic for intrapartumantibiotic
prophylaxis. Also, a very low resistance rate recorded for erythro-
mycin and clindamycin in this study implied that women allergic
to -lactam antibiotics can alternatively receive intravenous clin-
damycin or erythromycin.
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Infections after Biologic Agent Therapy in
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Background: Biologic therapies for rheumatologic diseases,
which are targeted at molecules involved in the mechanisms
of the immune system, provide an alternative to the existing
treatment methods of disease-modifying anti-rheumatic drugs
and other immunosuppressive medications. Biologic agents have
demonstrated efﬁcacy in inﬂammatory rheumatic diseases (IRDs).
However, the drugs have side effects, inparticular increased risk of
bacterial and viral infection.
Methods & Materials: 705 patients with rheumatic diseases
who received biologics treatment evaluated for the presence of
active infection by clinical examination, blood count, urine anal-
ysis, liver function tests, chest X-ray, HbsAg, Anti-HCV, tuberculin
skin test and bacterial and tuberculosis culture study if necessary.
Results: Patients (Ankylosing Spondylitis (AS):329; Entero-
pathic Arthritis (EA):64; Psoriatic Arthritis (PSA):44; Rheumatoid
Arthritis (RA):175; Behcet’s Disease (BD):34; Familial Mediter-
renean Fever (FMF):21; Juvenile Rheumatoid Arthritis (JRA):10;
Others:26) were identiﬁed by reviewing the medical records
treated with biologic agents; abatacept (2%); adalimumab (33%),
inﬂiximab (24.4%), golimumab (2.6%), rituximab (10.7%), anakinra
(1.7%), canacinumab (0.1%), tocilizumab (1%) or etanercept (24.3%)
between 2003 and 2012. Mean disease duration was 9.95±7.73
